Browsing: Novo Nordisk

The landscape of diabetes medication is shifting yet again. Approved by the US Food and Drug Administration, a new generic…

Novo Nordisk has introduced its combination drug, CagriSema, in a recent major trial to challenge Eli Lilly’s Zepbound. This long-standing…

Recent revelations have brought to light concerning associations between compounded semaglutide and numerous adverse events, raising questions on drug safety.…